About UsWe started Reagency because, as scientists ourselves, we know how expensive and difficult it is to source the cutting-edge research compounds you may have seen in the recent literature.
What We Do
You only pay when we make it, and you only pay for what you need.
Just tell us what you want and we'll take care of the rest...
Seen something on Reagency a colleague might be interested in? Share it with them. If they buy it, you'll earn credit towards your next Reagency purchase. We also reward the submission of reagents that reach production and citing Reagency in a peer reviewed journal. More information on Reagency rewards can be found here.
If you anticipate needing more material for an additional studies, you can reserve additional materials from the same batch and we'll kept aside for a period of 6 months until you are ready to purchase it. For more information on this service, click here or give us a call.
Who We Are
The Reagency team come from diverse backgrounds, but we all have science in common, so we understand the needs of both academic and commercial researchers. Take a minute to meet the team.
Prof. Andrew Wilks FTSE
Co-Founder, Director and Scientific Advisor
Andrew Wilks brings a wealth of knowledge and experience from the scientific and business worlds to Reagency. Andrew has had a long and successful academic career in kinase research, highlighted by the discovery and naming of the JAK family of tyrosine kinases. Andrew is also the founder of Cytopia and co-founder of SYNthesis med chem and SYNkinase and has a proven track record of successful enterprise foundation. His credentials are further bolstered by his experience serving on a number of for-profit and not-for-profit boards and advisory committees for Australian and international businesses and institutions. Andrew holds an adjunct Professorial appointment at Monash University, and is a WEHI Fellow at the Walter and Eliza Hall Institute. He was elected to the Australian Academy of Technological Sciences and Engineering in 2007. He has particular expertise in small molecule drug discovery, cell signalling and proteomics.
Professor Roger Daly PhD
Roger Daly brings his vast research and management experience to Reagency. Roger is currently Professor of Signalling Network Biology and Head of the Department of Biochemistry and Molecular Biology at Monash University. He has previously held research positions at the Imperial Cancer Research Fund, London, New York University Medical Centre and led the Signal Transduction Group at the Garvan Institute of Medical Research from 1993-2012. Roger’s innovative and cutting-edge research in tyrosine kinase signalling has kept him at the forefront of cancer research.
Mike Fussell MBioEnt, B.Sc.
Prior to graduating from Auckland University's Master of Bioscience Enterprise program, Mike developed and commercialized an imaging platform for asset management, structural engineering and aerospace applications.
Dr. Mary Saleh PhD
Dr. Mary Saleh brings over 25 years of experience in R&D, project management and commercialization to the mix. Mary has worked in or managed research laboratories at prestigious institutes and companies including The Salk Institute for Biological Sciences, Prince Henry’s Institute for Medical Research, The University of Melbourne and Metabolic Pharmaceuticals. She is an Adjunct Senior Research Fellow with Monash University. Mary is uniquely placed to apply her invaluable management and scientific expertise to Reagency and to drive the growth and expansion of the company.
Sales, Marketing and Business development Director
Leanne has unparalleled experience in sales, marketing and business development within the pharmaceutical and biotechnology industry. Her background in pharmacy and years of work supporting cell signaling research has helped Leanne forge a connection with the research community that makes her a key member of the Reagency team. Leanne ensures Reagency stays focused on what is most important - meeting our customers’ needs.